Skip to main content
Premium Trial:

Request an Annual Quote

Avantra Biosciences Starts Shipments of Q400 Biomarker Workstation

Premium

Avantra Biosciences announced this week the first shipments of its Q400 Biomarker Workstation and Angio Qx BioChip immunoassay for the study of tumor vascularization.

The shipments mark the culmination of the long journey back to the market for the platform. Originally developed by defunct biotech firm Decision Biomarkers, the platform was purchased in bankruptcy court with the rest of Decision's assets in December 2009 by Courtagen Capital Group, which launched Avantra in July of last year.

At that time, Elizabeth Holland, spokesperson for Courtagen and Avantra, told ProteoMonitor that the company planned to begin selling the workstation in early 2011 (PM 7/23/2010). In August of last year Avantra raised $7 million in equity funding (GWDN 08/18/2010).

Currently a research-use-only device, the Q400 consists of an assay-processing and fluorescence-imaging platform and disposable biochips that contain all the reagents required for performing multiplex biomarker assays. The company plans to seek regulatory approval for the platform and its assays in the future.

The shipment of the Q400 and the Angio Qx assay are "the first milestone in Avantra's strategy to develop a suite of oncology focused multiplex biomarker panels," Avantra CEO Brian McKernan said in statement.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.